# Circadian Disruption Through Light–Dark Cycle Alteration Induced Alzheimer’s Disease-like Pathology in Mice

**Authors:** Guojie Zhao, Bo Cui, Yue Lu, Kefeng Ma, Xiujie Gao, Xiaojun She, Yingwen Zhu, Xiang Ji, Honglian Yang

PMC · DOI: 10.3390/biom16020200 · Biomolecules · 2026-01-28

## TL;DR

Disrupting the light-dark cycle in mice caused Alzheimer's-like brain changes, suggesting that circadian rhythm disruption may contribute to the disease.

## Contribution

Demonstrates that circadian disruption induces Alzheimer’s-like pathology in mice through specific molecular mechanisms.

## Key findings

- CD increased amyloid-beta and hyperphosphorylated tau in the hippocampus.
- CD disrupted circadian clock genes and neurotransmitter rhythms in the hippocampus.
- CD caused neuroinflammation and reduced blood-brain barrier proteins in mice.

## Abstract

Circadian disruption (CD) has emerged as a critical factor compromising human health in contemporary society. Increasing evidence suggests that disturbances in circadian rhythms are involved in the pathogenesis of neurodegenerative diseases, such as Alzheimer’s disease (AD). The hyperphosphorylation of tau and the deposition of amyloid-β (Aβ) are recognized as major pathological hallmarks of AD. In this study, we aimed to explore the impact of long-term CD on AD-like pathological changes and to explore the underlying molecular mechanisms using a mouse model. To mimic the CD experienced by shift workers, mice were subjected to lighting conditions involving repeated reversals of the light–dark cycle. In this study, qPCR was to employed detect the expression profile of clock genes in the hippocampus. Subsequently, Western blotting and immunohistochemical analyses were used to evaluate AD-like pathological changes in the hippocampus following CD. For elucidating the underlying mechanisms, we assessed circadian expression patterns of major neurotransmitters, activation of microglia and astrocytes, and alterations of tight junction proteins within the hippocampus. Our findings demonstrated that light–dark cycle disruption triggered CD in mice, and then CD led to increased expression of Aβ protein and tau hyperphosphorylation. CD significantly disrupted the circadian expression profiles of hippocampal clock genes and major neurotransmitters, induced microglial and astrocytic activation, and decreased the expression of the tight junction proteins zonula occludens-1 and occludin in the hippocampus. These results suggest that changes in the light–dark cycles induced abnormal expression of hippocampal clock genes involved in circadian rhythm regulation, suggesting that the body is in a state of endogenous CD. CD induces AD-like pathological changes in mice, potentially mediated by dysregulated circadian oscillations of clock genes, neuroinflammation, loss of key blood–brain barrier proteins, and disturbed neurotransmitter expression in the hippocampus. Collectively, this study underscores the importance of circadian stability for brain health, and highlights the necessity for deeper exploration into the connection between AD and CD.

## Linked entities

- **Proteins:** MAPT (microtubule associated protein tau), si:ch73-61d6.3 (uncharacterized si:ch73-61d6.3)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Psen2 (presenilin 2) [NCBI Gene 19165] {aka ALG-3, Ad4h, Alg3, PS-2, PS2, Psnl2}, Ciart (circadian associated repressor of transcription) [NCBI Gene 229599] {aka Chrono, Gm129}, Cldn5 (claudin 5) [NCBI Gene 12741] {aka MBEC1, Tmvcf}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, Nr1d1 (nuclear receptor subfamily 1, group D, member 1) [NCBI Gene 217166] {aka A530070C09Rik}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, CRY2 (cryptochrome circadian regulator 2) [NCBI Gene 1408] {aka HCRY2, PHLL2}, Bmal1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 11865] {aka Arnt3, Arntl, BMAL1b, MOP3, bHLHe5, bmal1b'}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, Clock (clock circadian regulator) [NCBI Gene 12753] {aka 5330400M04Rik, KAT13D}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], Cldn1 (claudin 1) [NCBI Gene 12737], BMAL1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 406] {aka ARNTL, ARNTL1, BMAL1c, JAP3, MOP3, PASD3}, Ctsd (cathepsin D) [NCBI Gene 13033] {aka CD, CatD}, Cry1 (cryptochrome circadian regulator 1) [NCBI Gene 12952] {aka Phll1}, Ocln (occludin) [NCBI Gene 18260] {aka Ocl}, Per1 (period circadian clock 1) [NCBI Gene 18626] {aka Hftm, Per, m-rigui, mPer1}, Per2 (period circadian clock 2) [NCBI Gene 18627] {aka mKIAA0347, mPer2}, CLOCK (clock circadian regulator) [NCBI Gene 9575] {aka KAT13D, bHLHe8}, Dbp (D site albumin promoter binding protein) [NCBI Gene 13170], Nr1d2 (nuclear receptor subfamily 1, group D, member 2) [NCBI Gene 353187] {aka RVR, Rev-erb}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], PER2 (period circadian regulator 2) [NCBI Gene 8864] {aka FASPS, FASPS1}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}
- **Diseases:** amyloid (MESH:C000718787), dementia (MESH:D003704), Ach (MESH:C536090), sleep deprivation (MESH:D012892), amyloidosis (MESH:D000686), neuronal loss (MESH:D009410), memory impairment (MESH:D008569), NFTs (MESH:D055956), cognitive and behavioral impairments (MESH:D003072), amyloid plaques (MESH:D058225), sleep dysregulation (MESH:D021081), mitochondrial dysfunction (MESH:D028361), sleep disturbances (MESH:D012893), brain insults (MESH:D001927), deficiencies (MESH:D007153), Astrogliosis (MESH:D005911), DA (MESH:C567730), neurotransmitter abnormalities (MESH:D000014), neurodegeneration (MESH:D019636), injury to (MESH:D014947), inflammation (MESH:D007249), aphasia (MESH:D001037), cerebral capillary damage (MESH:D020786), Neuroinflammation (MESH:D000090862), BBB (MESH:C536830), CD (MESH:D019958), AD (MESH:D000544), neurotoxic (MESH:D020258)
- **Chemicals:** Ach (MESH:D000109), 5-HTP (MESH:D006916), bicinchoninic acid (MESH:C047117), water (MESH:D014867), glycine (MESH:D005998), calcium (MESH:D002118), 5-HT (MESH:D012701), ethanol (MESH:D000431), 4',6-diamidino-2-phenylindole (MESH:C007293), polyvinylidene difluoride (MESH:C024865), Glu (MESH:D018698), GABA (MESH:D005680), DA (MESH:D004298), hematoxylin (MESH:D006416), melatonin (MESH:D008550), hydrogen peroxide (MESH:D006861), 3,3'-diaminodbenzidine (-), paraffin (MESH:D010232), polyacrylamide (MESH:C016679)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** R47H
- **Cell lines:** /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938483/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938483/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938483/full.md

---
Source: https://tomesphere.com/paper/PMC12938483